adamantane has been researched along with Shingles in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, M; Kaneko, Y; Kato, D; Miyatake, D; Takeuchi, T; Tanaka, Y | 1 |
| Fukuda, M; Izutsu, H; Kaneko, Y; Kato, D; Rokuda, M; Takeuchi, T; Tanaka, Y | 1 |
| Chen, YH; Izutsu, H; Kaneko, Y; Kawakami, A; Nakashima, Y; Rokuda, M; Shiomi, T; Song, YW; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; Yamada, E | 1 |
| Morinobu, A | 1 |
| Kaneko, Y | 1 |
| Iwasaki, M; Izutsu, H; Kaneko, Y; Katayama, K; Kawakami, A; Rokuda, M; Shiomi, T; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; van der Heijde, D; Yamada, E | 1 |
| Akazawa, R; Chen, YH; Iwasaki, M; Izutsu, H; Kaneko, Y; Kawakami, A; Lee, SH; Rokuda, M; Shiomi, T; Song, YW; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; Wei, JC; Yamada, E | 1 |
3 review(s) available for adamantane and Shingles
| Article | Year |
|---|---|
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Herpes Zoster; Humans; Niacinamide; Prednisolone | 2022 |
JAK inhibitors for the treatment of rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism | 2020 |
Efficacy and safety of peficitinib in rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Herpes Zoster; Humans; Janus Kinases; Niacinamide; Protein Kinase Inhibitors | 2020 |
4 trial(s) available for adamantane and Shingles
| Article | Year |
|---|---|
Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis.
Topics: Adamantane; Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Herpes Zoster; Humans; Middle Aged; Niacinamide; Treatment Outcome; Young Adult | 2022 |
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Topics: Adamantane; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Female; Herpes Zoster; Humans; Janus Kinase Inhibitors; Japan; Male; Methotrexate; Middle Aged; Nasopharyngitis; Niacinamide; Republic of Korea; Severity of Illness Index; Taiwan; Treatment Outcome | 2020 |
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Topics: Adamantane; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Substitution; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Infections; Janus Kinase Inhibitors; Japan; Male; Methotrexate; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2019 |
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Topics: Adamantane; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Double-Blind Method; Drug Substitution; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Infections; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Niacinamide; Severity of Illness Index; Treatment Outcome | 2019 |